Ann: REVA Enters Peripheral Artery Disease Space with MOTIV, page-2

REVA Medical, Inc. (RVA) reported that its MOTIV bioresorbable scaffold is the first drug-eluting bioresorbable scaffold to receive CE Mark approval for treatment of below the knee peripheral artery disease. Late last year, REVA announced its plans to expand use of its bioresorbable scaffold technology in peripheral artery disease. The approval of MOTIV delivers that milestone and for the first time brings bioresorbable technology to this patient population.

http://crweworld.com/article/news-p...resorbale-scaffold-for-below-the-knee-therapy